Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Pearce IP BioBlast®: w/e 04 June 2021

by | Jun 7, 2021

31 May 21 | Celltrion will launch Yuflyma® (biosimilar adalimumab) in the EU in June, as reported by the Korea Herald.  Citing ‘industry sources’ and a Celltrion official, the Korea Herald discloses that Celltrion will initially launch Yuflyma® in six EU countries including Spain, before launching in an additional 7 EU countries in Q3 2021, and 3 more in Q4 2021.

01 June 21 | Celltrion presented one-year data for Yuflyma® (biosimilar adalimumab). Celltrion reported that this data demonstrates comparable efficacy and safety to the reference product in patients with rheumatoid arthritis.

01 June 21 | Biogen and Bio-Thera announced results from Ph III trials of BAT1806 (proposed tocilizumab biosimilar) demonstrating equivalence to the reference product in patients with rheumatoid arthritis.

02 June 21 | US | Lupin announced the FDA has accepted the BLA for its proposed pegfilgrastim biosimilar.

Did you know that you can subscribe to Pearce IP’s updates including our weekly BioBlast® and regular pharma and IP industry news? Click here to receive these updates directly in your inbox.





Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News